Multiple Sclerosis Clinical Trial

Teriflunomide’s Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.

Summary

The purpose of this research is to characterize the effect of teriflunomide on the activation of B-cells, as well as its capacity to modify B-cell cytokine secretion. The in-vitro identified effects of teriflunomide on the expression of B-cell activation markers, costimulatory and antigen presenting molecules, as well as on cytokine secretion, will then be confirmed in a cohort of Relapsing Remitting Multiple Sclerosis (RRMS) patients treated with this medication.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

confirmed diagnosis of RRMS according to McDonald's diagnostic criteria,
age 18-55,
an extended disability status score (EDSS) of 1.5-5.5.

Exclusion Criteria:

- Previous treatment with DMT.

Study is for people with:

Multiple Sclerosis

Estimated Enrollment:

26

Study ID:

NCT02833714

Recruitment Status:

Terminated

Sponsor:

University of North Carolina, Chapel Hill

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University of North Carolina
Chapel Hill North Carolina, 27599, United States

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Estimated Enrollment:

26

Study ID:

NCT02833714

Recruitment Status:

Terminated

Sponsor:


University of North Carolina, Chapel Hill

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider